ReviewInternational journal of antimicrobial agents2014
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.
Review in International journal of antimicrobial agents, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials inAntimicrobial agents and chemotherapy · 2025Article
- Therapeutic Potential of Salvianolic Acid B Produced by Streptomyces sp. M4 Against Multi-drug-Resistant Human Pathogens.Current microbiology · 2025Article
- Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy.BMC microbiology · 2024Review
- Article
- Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDRAntibiotics (Basel, Switzerland) · 2022Article
- Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections.Current infectious disease reports · 2019Review
- Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Observational
- Reduced Chlorhexidine and Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium after Serial Chlorhexidine Exposure.Antimicrobial agents and chemotherapy · 2018Article
- Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in anAntimicrobial agents and chemotherapy · 2017Article
- Article
- An Adaptive Mutation in Enterococcus faecium LiaR Associated with Antimicrobial Peptide Resistance Mimics Phosphorylation and Stabilizes LiaR in an Activated State.Journal of molecular biology · 2016Article
- Review
- Exogenous Fatty Acids Protect Enterococcus faecalis from Daptomycin-Induced Membrane Stress Independently of the Response Regulator LiaR.Applied and environmental microbiology · 2016Article
- Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.Infection · 2016Review
- Article
- Mechanisms of drug resistance: daptomycin resistance.Annals of the New York Academy of Sciences · 2015Review
- In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.